BNP/CALL/ASTRAZENECA/13000/0.1/19.12.25 | Market Closed - Börse Stuttgart 04:22:42 2024-05-17 am EDT | ||
| 1.62 EUR | 0.00% |
|
| Current month | +1.89% | ||
| 1 month | +63.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.62 | 0.00% |
| 24-05-16 | 1.62 | -4.71% |
| 24-05-15 | 1.7 | -3.95% |
| 24-05-14 | 1.77 | -0.56% |
| 24-05-13 | 1.78 | -1.66% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 04:22 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC8HB8 |
| ISIN | DE000PC8HB84 |
| Date issued | 2024-04-17 |
| Strike | 13,000 p |
| Maturity | 2025-12-19 (579 Days) |
| Parity | 10 : 1 |
| Emission price | 0.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.81 € |
|---|---|
| Lowest since issue | 0.95 € |
| Spread | 0.02 € |
| Spread % | 1.23% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.7
USD
Spread / Average Target
+9.02%
- Stock Market
- Warrants
- Warrant
